AIM ImmunoTech Inc (AIM)
0.424
+0.02
(+4.31%)
USD |
NYAM |
Apr 26, 16:00
0.424
0.00 (0.00%)
After-Hours: 20:00
AIM ImmunoTech SG&A Expense (Quarterly): 10.86M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 10.86M |
September 30, 2023 | 5.439M |
June 30, 2023 | 2.55M |
March 31, 2023 | 2.292M |
December 31, 2022 | 3.505M |
September 30, 2022 | 5.17M |
June 30, 2022 | 2.181M |
March 31, 2022 | 2.072M |
December 31, 2021 | 2.617M |
September 30, 2021 | 1.799M |
June 30, 2021 | 2.145M |
March 31, 2021 | 2.112M |
December 31, 2020 | 2.584M |
September 30, 2020 | 2.085M |
June 30, 2020 | 1.717M |
March 31, 2020 | 2.268M |
December 31, 2019 | 1.484M |
September 30, 2019 | 1.846M |
June 30, 2019 | 1.942M |
March 31, 2019 | 1.767M |
December 31, 2018 | 1.632M |
September 30, 2018 | 1.273M |
June 30, 2018 | 1.733M |
March 31, 2018 | 1.563M |
December 31, 2017 | 1.733M |
Date | Value |
---|---|
September 30, 2017 | 1.556M |
June 30, 2017 | 1.619M |
March 31, 2017 | 1.664M |
December 31, 2016 | 1.96M |
September 30, 2016 | 1.634M |
June 30, 2016 | 1.639M |
March 31, 2016 | 2.448M |
December 31, 2015 | 1.547M |
September 30, 2015 | 1.685M |
June 30, 2015 | 2.002M |
March 31, 2015 | 1.913M |
December 31, 2014 | 1.847M |
September 30, 2014 | 2.174M |
June 30, 2014 | 2.497M |
March 31, 2014 | 2.539M |
December 31, 2013 | 1.759M |
September 30, 2013 | 2.07M |
June 30, 2013 | 1.817M |
March 31, 2013 | 2.077M |
December 31, 2012 | 3.785M |
September 30, 2012 | 1.659M |
June 30, 2012 | 1.738M |
March 31, 2012 | 1.874M |
December 31, 2011 | 1.801M |
September 30, 2011 | 1.635M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
1.484M
Minimum
Dec 2019
10.86M
Maximum
Dec 2023
2.982M
Average
2.181M
Median
Jun 2022
SG&A Expense (Quarterly) Benchmarks
Perspective Therapeutics Inc | 1.694M |
Protalix BioTherapeutics Inc | 4.143M |
Electromed Inc | 8.175M |
Xtant Medical Holdings Inc | 20.45M |
Armata Pharmaceuticals Inc | 3.179M |